Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HUC2-344 (Empagliflozin + Metformin) in Healthy Volunteers
NCT06551740Phase 1Completed
- Sponsor
- Huons
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Huons. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time to Maximum Concentration at 48 hours and 1 more. Started Apr 2024; status: completed.
02
Drugs
empagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06551740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551740.